Silence Therapeutics plc
SLNNASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $929.14M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $4.19$19.65
- Volume (live)
- -
- Avg. volume (3M)
- 4.03M
Silence Therapeutics (SLN) Stock Price & Financial Analysis
Silence Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $19.65 - $19.68 |
|---|---|
| 52-Week High | $19.65 |
| 52-Week Low | $4.19 |
| Open | $19.65 |
| Volume (last close) | 2.13M |
| Average Volume (3M) | 4.03M |
| Revenue (TTM) | 614.29K |
|---|---|
| Net Income (TTM) | -59.93M |
| Free Cash Flow (TTM) | -42.27M |
| EPS (TTM) | −$1.90 |
| Profit Margin | -9755.61% |
| Operating Margin | -11003.04% |
| Return on Equity (ROE) | -155.77% |
| Debt to Equity | 0.00 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 929.14M |
|---|---|
| Shares Outstanding | 47.24M |
| Price to Sales (P/S) | 1512.54 |
| Price to Book (P/B) | 24.15 |
| EV/EBITDA | -12.78 |
| 50-Day MA | $12.55 |
|---|---|
| 200-Day MA | $8.50 |
| 1-Year Change | +171.17% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
Silence Therapeutics at a Glance
As of the Oct 23, 2026 close, Silence Therapeutics (SLN) has a market capitalization of $929.14M. The stock trades at 1512.5× sales. Over the trailing twelve months it lost $59.93M on revenue of $614.29K and burned $42.27M of free cash flow. Revenue fell 97.6% year over year.
As of its latest reported balance sheet, it holds $72.05M in cash and securities against $112.00K of debt, a net cash position of $71.94M.
Silence Therapeutics does not currently pay a dividend.
The share price is up 171.2% over the past year. At $19.67 (the Oct 23, 2026 close) it sits near the top of its 52-week range of $4.19 to $19.65, above its 200-day moving average of $8.50.
Based on 6 professional analyst ratings from the past 90 days, the consensus is Hold with an average price target of $23.00, 16.9% above the Oct 23, 2026 close.
Frequently Asked Questions About Silence Therapeutics
What is the current stock price for SLN?
As of the Oct 23, 2026 close, SLN stock trades at $19.67. The 52-week range is $4.19–$19.65, with a day range of $19.65–$19.68.
What is the P/E ratio for SLN?
The P/E ratio (Price-to-Earnings) for SLN is shown in the Key Statistics section. This valuation metric helps compare Silence Therapeutics plc to industry peers.
Does SLN pay dividends?
Silence Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for SLN?
Based on ratings from 6 professional analysts over the last 90 days, the consensus for SLN is Hold. The average 12-month price target is $23.00, a 16.9% upside from the Oct 23, 2026 close of $19.67.
What is the market cap of SLN?
As of the Oct 23, 2026 close, Silence Therapeutics's market capitalization is $929.1M, classifying it as a small-cap company. Silence Therapeutics operates in the Healthcare sector within the Biotechnology industry.